Don’t give this to your daughter – despite what your doctor says. ~ From Mercola.com

It’s been four years since Gardasil debuted as a blockbuster vaccine with sales that rocketed to over $1.1 billion in its first nine months.

Touted as a wonder vaccine that would end cervical cancer, it was supposed to be the savior of both mankind and Merck’s Vioxx-damaged bottom line. But now, according to CNN Money, it’s a dud.

It just posted $219 million in sales. But in the pharma world, that’s a paltry pittance, nothing short of an in-flight explosion that’s caused Merck stock to drop 3 percent, with analysts and investors scrambling to figure out what went wrong.

So what happened?

How did a vaccine that was supposed to be Merck’s beacon for higher profits in the 21st Century go from flagship to flop?

Read the entire article here

Print Friendly, PDF & Email

Bad Behavior has blocked 142 access attempts in the last 7 days.